Lv3
276 积分 2025-04-28 加入
Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis
4天前
已完结
Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis
13天前
已完结
The novel lysophosphatidic acid receptor 1-selective antagonist, ACT-1016-0707, has unique binding properties that translate into effective antifibrotic and anti-inflammatory activity in different models of pulmonary fibrosis
18天前
已完结
Discovery of a Novel Orally Active, Selective LPA Receptor Type 1 Antagonist, 4-(4-(2-Isopropylphenyl)-4-((2-methoxy-4-methylphenyl)carbamoyl)piperidin-1-yl)-4-oxobutanoic Acid, with a Distinct Molecular Scaffold
23天前
已完结
Discovery of the Novel, Orally Active, and Selective LPA1 Receptor Antagonist ACT-1016-0707 as a Preclinical Candidate for the Treatment of Fibrotic Diseases
23天前
已完结
The novel lysophosphatidic acid receptor 1-selective antagonist, ACT-1016-0707, has unique binding properties that translate into effective antifibrotic and anti-inflammatory activity in different models of pulmonary fibrosis
23天前
已完结
Structure Based Discovery and Anti-fibrotic Activity of Novel Antagonists of Lysophosphatidic Acid Receptor 1 (LPAR1)
24天前
已关闭
ABS0269 LPA1/3 DUAL ANTAGONIST AMELIORATED SYSTEMIC SCLEROSIS MORE EFFECTIVE THAN LPA1 SELECTIVE ANTAGONIST VIA SUPPRESSING LPA3 PATHWAY IN SKIN
24天前
已关闭
LPA1 antagonists BMS-986020 and BMS-986234 for idiopathic pulmonary fibrosis: Preclinical evaluation of hepatobiliary homeostasis
24天前
已关闭
Pharmacokinetics of Fipaxalparant, a Small‐Molecule Selective Negative Allosteric Modulator of Lysophosphatidic Acid Receptor 1, and the Effect of Food in Healthy Volunteers
24天前
已完结
皖公网安备34019202002308
